Astellas and Yaskawa to form joint venture for cell therapy manufacturing

Astellas Pharma and Yaskawa Electric have signed a definitive agreement to establish a joint venture to develop a cell therapy product manufacturing platform using Yaskawa's dual-arm robot 'Maholo'. The joint venture will also offer platform access to startups and academic institutions. Capital is 4.5 billion yen, with Astellas holding 60% and Yaskawa 40%. Establishment is tentatively set for September 2025.

“Astellas Pharma Inc. and YASKAWA Electric Corporation signed a definitive agreement to establish a joint venture for the development of a cell therapy product manufacturing platform utilizing the dual-arm robot 'Maholo'.”newsroom.astellas.com

• 1 source
• newsroom.astellas.comGlobal News | AstellasMar 6, 2025

Summarized from public sources; check the original articles before acting on it.